aTyr Pharma, Inc.
NASDAQ:ATYRBiotechnology
+$0.07 today
- Market cap
- $52.13M
- Beta
- 0.54
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$0.71
Volume 1.02M
Average 2.29M
ATYR Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
aTyr Pharma, Inc.NASDAQ: ATYR
Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026
Cash & equivalents falls 3.4% from a year ago
Cash & equivalents stood at $10.01M at the end of Q1 FY2026, down 3.4% from a year earlier and down 6.8% from the prior quarter. Over 3 fiscal years it compounded at +2.5% a year.
Context
- Cash & equivalents amounted to 12.6% of total assets at the end of Q1 FY2026, up 1.9 pp from a year earlier.
- Cash & equivalents increased in 1 of the last 3 fiscal years.
What to watch
Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -3.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2025
- 10.74M USD
- Year-over-year change
- -2.8%
- 4-year CAGR
- +46.4%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10.74M | -2.8% |
| FY2024 | 2024-12-31 | 11.06M | -51.0% |
| FY2023 | 2023-12-31 | 22.54M | +125.9% |
| FY2022 | 2022-12-31 | 9.98M | +327.3% |
| FY2021 | 2021-12-31 | 2.34M | — |
Cash & Equivalents vs competitors
How ATYR compares with its peers on the latest reported figures
- Peers report in different currencies, so cash & equivalents is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -3.4% is the 7th highest of 8, against a peer median of +56.6%.
- Cash & equivalents amounts to 12.6% of total assets for ATYR, versus a peer median of 58.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $99.37M USD | +28.7% | -16.4% | 69.1% | |
| Mar 2026 | $99.21M USD | +101.1% | — | 94.1% | |
| Mar 2026 | $37.37M USD | +89.0% | +300.4% | 58.0% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | Mar 2026 | $34.06M USD | -13.0% | +12.0% | 31.6% |
| Mar 2026 | $32.28M USD | +56.6% | -30.5% | 18.1% | |
HYFTMindWalk Holdings Corp. | Jan 2026 | CA$14.18M CAD | +9.8% | -29.1% | 61.2% |
| Mar 2026 | $10.01M USD | -3.4% | +2.5% | 12.6% | |
| Mar 2026 | $9.78M USD | +750.3% | -13.5% | 4.2% | |
| Peer median (excluding ATYR) | — | +56.6% | -14.9% | 58.0% | |
Competitors are the stored peer set for ATYR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 2.34M | 9.98M | 22.54M | 11.06M | 10.74M |
| Short-term Investments | 105.58M | 56.17M | 75.62M | 61.07M | 67.94M |
| Net Receivables | 435K | 11.78M | 2.44M | 1.74M | 873K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | 113.57M | 80.87M | 102.99M | 81.95M | 80.24M |
| Property, Plant & Equipment (Net) | 1.81M | 11.56M | 14.05M | 11.86M | 10.38M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 2.24M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 158K | 3.36M | 3.62M | 3.02M | 1.31M |
| Total Non-current Assets | 1.97M | 14.92M | 17.66M | 14.88M | 13.93M |
| Total Assets | 115.54M | 95.79M | 120.65M | 96.83M | 94.16M |
| Account Payables | 1.03M | 3.11M | 3.53M | 4.32M | 3.89M |
| Short-term Debt | 0 | 0 | 0 | 0 | 1.47M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 6.81M |
| Total Current Liabilities | 6.01M | 13.86M | 16.42M | 14.97M | 15.15M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 1.16M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 398K | 10.64M | 13.77M | 12.03M | 11.73M |
| Total Liabilities | 6.41M | 24.5M | 30.18M | 27M | 26.88M |
| Common Stock | 28K | 29K | 63K | 84K | 98K |
| Retained Earnings | (372.3M) | (417.63M) | (468.02M) | (532.05M) | (606.16M) |
| Accumulated OCI | (263K) | (433K) | (74K) | (40K) | (8K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | (175K) | (180K) | (188K) | (187K) | (192K) |
| Total Equity | 109.13M | 71.28M | 90.47M | 69.83M | 67.29M |
| Total Debt | 1.38M | 11.53M | 15.1M | 13.28M | 12.03M |
| Net Debt | (958K) | 1.55M | (7.45M) | 2.23M | 1.29M |
aTyr Pharma, Inc.
NASDAQ:ATYR
Intrinsic Alpha fair value
Locked
Current Price
$0.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.